Skip to main content
Medical information Clinical review pending

Genetic Testing

GBA Gene Gaucher Disease Type 3 Genetic Test

This genetic test identifies mutations in the GBA gene associated with Gaucher disease type 3, a metabolic disorder. It uses Next Generation Sequencing (NGS) technology to analyze DNA. Recommended for individuals with symptoms like enlarged spleen or liver, or a family history of the disease.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific fasting is required. Inform the laboratory of any relevant clinical history and family history of Gaucher disease.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the GBA Gene Gaucher Disease Type 3 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of Gaucher disease type 3 (e.g., enlarged spleen or liver, neurological symptoms).
  • ✓Individuals with a known family history of Gaucher disease.
  • ✓Carrier screening for individuals with a family history of Gaucher disease.
  • ✓Confirmation of diagnosis in suspected cases.
02

In plain language

What this test helps you understand

This test helps diagnose Gaucher disease type 3 by identifying mutations in the GBA gene. Early diagnosis allows for appropriate management and potential treatment options.
The GBA Gene Gaucher Disease Type 3 NGS Genetic DNA Test is a specialized genetic test designed to identify mutations in the GBA gene, which are responsible for Gaucher disease type 3. This disorder is a type of metabolic disorder that can lead to severe health complications. Early diagnosis is crucial, as it allows for timely management and treatment options.

This test measures the presence of specific mutations in the GBA gene. By utilizing Next Generation Sequencing (NGS) technology, the test provides a comprehensive analysis of the genetic material, enabling accurate detection of Gaucher disease type 3.

Individuals who may benefit from this test include those exhibiting symptoms such as spleen or liver enlargement, individuals with a family history of Gaucher disease type 3, and patients experiencing unexplained neurological symptoms or other related health issues.

The GBA Gene Gaucher Disease Type 3 NGS Genetic DNA Test offers several benefits, including early diagnosis of Gaucher disease type 3, informed decision-making regarding treatment options, access to genetic counseling for family planning and management, and understanding your genetic predisposition to the disease.

Once you receive your test results, it is essential to consult with a healthcare professional to interpret the findings. A positive result may indicate the need for further evaluations and discussions regarding treatment options. Genetic counseling can provide valuable insights into the implications of your results and the best steps forward.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific fasting is required. Inform the laboratory of any relevant clinical history and family history of Gaucher disease.
SampleBlood sample (EDTA tube). Confirm with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the GBA gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects mutations in the GBA gene known to cause Gaucher disease type 3. It may not detect all possible mutations. A negative result does not completely rule out the condition. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Gaucher disease type 3 is a rare genetic metabolic disorder caused by mutations in the GBA gene. It can lead to various health problems, including neurological symptoms.
Testing is recommended for individuals showing symptoms like enlarged spleen or liver, those with unexplained neurological issues, or those with a family history of Gaucher disease.
The test uses Next Generation Sequencing (NGS) for comprehensive analysis. Discuss the specific accuracy and limitations with your doctor or the laboratory.
It's important to discuss your results with a healthcare professional or genetic counselor to understand their implications and plan next steps.
Yes, genetic counseling is recommended to help understand the test results, discuss family implications, and make informed decisions.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp